Ishitsuka, K. et al. evaluated the therapeutic potential of ABT-737, a novel small-molecule inhibitor of the BCL-2 family, in ATLL caused by HTLV-1 infection [55]. This evidence concerns the gene BCL2 and adult T-cell leukemia/lymphoma.